Skip to content

Speakers

Expand/Collapse

Lothar Steidler
Chief Technology Officer
ActoBio Therapeutics

Andrea Doolan
CEO
Atlantia Food Clinical Trials

Rikke Nielsen
CEO & Founder
Beo Therapeutics

Day Two

Thursday 6th February 2020

4:30 pm | Panel title: The borderline between Pharma and Food – How is the Microbiome is Blurring the Lines?

4:00 pm | Optimising the Gut Microbiome to Rebalance Urate Metabolism and Pre-empt Hyperuricemia

Adrien Nivoliez
CEO
biose industrie

Elran Haber
CEO
Biomica Ltd.

Day Two

Thursday 6th February 2020

10:00 am | Panel Discussion: Where do we Stand with Current Innovation & Future Integration of Microbiome-Based Approaches into Routine Oncology Practice?

Assaf Oron
Chief Business Officer
BiomX

Dorottya Nagy-Szakal MD
Chief Medical Officer
Biotia, Inc.

Day One

Wednesday 5th February 2020

4:30 pm | Harnessing the Microbiome to Develop Breakthrough Diagnostic Tools

Jeffrey Heiser
Director Microbiology
Boston Analytical

Day One

Wednesday 5th February 2020

10:00 am | Gut Microbiome Endgame: Ramping up cGMP Program Design to Ensure Regulatory Preparedness for Microbiome Products

Luc Sterkman
CEO
Caelus Health

Day One

Wednesday 5th February 2020

4:30 pm | How Can Industry Partners Streamline Regulatory Guidelines for Microbiome-based Therapeutics?

Arne Materna
Vice President Product
CosmosID

Day One

Wednesday 5th February 2020

9:30 am | Shotgun Sequencing & Strain-Level Analysis: Study Design for Pre-Clinical & Clinical Development

Jean de Gunzburg
CSO
DaVolterra

Sebastien Guery
Human Microbiome Venture Leader
Dupont Microbiome Venture

Day Two

Thursday 6th February 2020

4:30 pm | Panel title: The borderline between Pharma and Food – How is the Microbiome is Blurring the Lines?

Igor Stzepourginski
Head of Preclinical Operations
Eligo Biosciences

Romain D’Ailiere
Head of Preclinical Research & Co-Founder
EverImmune

Day Two

Thursday 6th February 2020

10:00 am | Panel Discussion: Where do we Stand with Current Innovation & Future Integration of Microbiome-Based Approaches into Routine Oncology Practice?

9:30 am | Improving Cancer Treatment Through Oncobax-Based Therapeutics

Rafael Suarez
Senior Director Emerging Brands, Global Marketing, Gastroenterology & Mirobiome
Ferring Pharmaceuticals

Kristin Wannerberger
Director R&D Alliance Management
Ferring Pharmaceuticals

Anna Williamson
Senior Director Oncology Business & Head of UK Business Development
Genentech

Suhyun Kim
Postdoctoral fellow
Harvard University

Shahram Lavasani
CEO & Founder
Immune Biotech

Day Two

Thursday 6th February 2020

4:30 pm | Panel title: The borderline between Pharma and Food – How is the Microbiome is Blurring the Lines?

3:30 pm | Leveraging Insights from Probiotic Combinations to Develop the Next Generation Live BioTherapeutics

Georges Rawadi
CEO
LNC Therapeutics

Jason Ryan
Upstream Manager
Luina Bio

Sophie Durand
Co-Founder
Microbiome Foundation

Day Two

Thursday 6th February 2020

4:30 pm | Panel title: The borderline between Pharma and Food – How is the Microbiome is Blurring the Lines?

Mike Romanos
CEO
Microbiotica

Day One

Wednesday 5th February 2020

8:30 am | Microbiome Leaders Panel Discussion

Trevor Lawley
CSO
Microbiotica

Day Two

Thursday 6th February 2020

10:00 am | Panel Discussion: Where do we Stand with Current Innovation & Future Integration of Microbiome-Based Approaches into Routine Oncology Practice?

8:30 am | Applying Microbiotica’s Platform to Modulate Cancer Immunotherapy Response & Identify Bacterial Biomarkers & Medicines

Herwig Bachmann
Expertise Group Leader Fermentation
NIZO

Maria Akerman
Director Process R&D
Oxthera

Tomas de Wouters
CEO & Co-Founder
PharmaBIome

Day One

Wednesday 5th February 2020

4:30 pm | Standalone Therapy or Co-Therapy: Where is the Microbiome Most Relevant?

8:30 am | Microbiome Leaders Panel Discussion

Aurelien Baudot
International Business Developer
ProDigest

Ryan Wilson
Head of Live-Bio Programmes
Quay Pharma

Ken Blount
CSO
Rebiotix

Alain Roulet
Laboratory Director
Vaiomer

Kareem Barghouti
Co-Founder
VastBiome

Bruce Roberts
CSO
Vedanta Biosciences

Day Two

Thursday 6th February 2020

10:00 am | Panel Discussion: Where do we Stand with Current Innovation & Future Integration of Microbiome-Based Approaches into Routine Oncology Practice?

Imke Mulder
Director of Research
4D Pharma

Day Two

Thursday 6th February 2020

10:00 am | Panel Discussion: Where do we Stand with Current Innovation & Future Integration of Microbiome-Based Approaches into Routine Oncology Practice?

9:00 am | Developing Live Biotherapeutics to Target Immuno-Oncology

Damien Keogh
CEO
Maiden Therapeutics

Christophe Lacroix
Professor, Food Biotechnology
ETH Zuric